The Russian company is a developer of innovative technology. It was founded in 1916 and over the years of its existence annually extol the contribution to innovation and development of the medical field.
There are a number of drugs with extremely low oral bioavailability. The only insignificant portion of a drug reaches the bloodstream when administrated orally. This requires more complex ways of taking the medicine: subcutaneous and intravenous injections. The basis of the developed technology is a unique multi-component oral administration system of drugs into the blood. The chemical composition based on modified chitosan is a nanostructured multi-layered matrix that implements transport and protective functions simultaneously. The composition in gel form inhibits the destruction of the medicine it transfers under the influence of proteolytic enzymes of the gastrointestinal tract while absorbing into the blood where it gradually decomposes and releases the drug without damaging the liver.
The chemical composition (the drug transport matrix) has been developed at the present moment. The structure obtained has been studied and the possibility of transferring various drugs has been determined. The primary tests on the bioavailability of insulin were carried out. Based on the results of preliminary tests of the new drug on small lab animals, the bioavailability of insulin with oral administration of the new drug is 20-25%.
First of all, an independent test on the bioavailability of the transferred medicines (on large lab animals in particular) and development of the reproducibility of substances are necessary for the further development of the project, after which it is possible to conduct preclinical trials of the drug.
The Russian organization is looking for new foreign partners from the medical field (pharmacological companies, medical research centers) to conclude a mutually beneficial commercial agreement with technical assistance or research cooperation agreements. Under the commercial agreement with technical assistance, the developers consider the sale of rights on technology, as there are no sufficient capacities at their disposal to do further research and for develop the product to its final form.
As a result of the research cooperation agreement, developers consider joint research and development. In this case, developers take on the task of developing the technology of the required drug. The tasks of conducting bioavailability tests by GMP standards and further preclinical trials remain for the partners.
